On the recordJanuary 31, 2012
The reauthorization of the FDA user fee program presents Congress with the opportunity to improve upon the current U.S. drug and device approval pathway.
Source
congress.govEditor's note · Context
Gingrey emphasizes the chance to enhance drug approval processes through reauthorization.
Share & report
More from Phil Gingrey
Jul 7, 2013
The maintenance of effort provisions in Obamacare have not only been costly, but they have been a barrier to reforms.
Mar 14, 2013
I feel very strongly that the States should be able to do that, and that is what this bill, the Liberty Act, is about.
Mar 19, 2013
I still believe in the amazing potential that health information technologies will have on the practice of medicine.
Other voices in this conversation
